Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use FYARRO safely and effectively. See full prescribing information for FYARRO. FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound), for intravenous useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
FYARRO® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
- generic_name
- sirolimus
- product_names
- Sirolimus
- ndc
- 80803-153, 80803-153-50
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en